doi:10.48130/targetome-0026-0033

[1]

Siegel RL, Kratzer TB, Wagle NS, Sung H, Jemal A. 2026. Cancer statistics, 2026. CA: A Cancer Journal for Clinicians 76:e70043

doi: 10.3322/caac.70043

[2]

Zhong G, Zhang X, Zhao R, Guo Z, Wang C, et al. 2025. The high efficacy of claudin18.2-targeted CAR-T cell therapy in advanced pancreatic cancer with an antibody-dependent safety strategy. Molecular Therapy 33:2778−2788

doi: 10.1016/j.ymthe.2025.01.012

[3]

Hilmi M, Delecourt F, Raffenne J, Bourega T, Dusetti N, et al. 2025. Redefining phenotypic intratumor heterogeneity of pancreatic ductal adenocarcinoma: a bottom-up approach. The Journal of Pathology 265:448−461

doi: 10.1002/path.6398

[4]

Zhang J, Westcott PMK. 2024. Claudin 18 turns up the heat in cancer. Immunity 57:1187−1189

doi: 10.1016/j.immuni.2024.05.015

[5]

Qing Y, Jiang K, Jiang H, Zhao Y, Lai CH, et al. 2025. CLDN18.2 CAR-derived extracellular vesicle immunotherapy improves outcome in murine pancreatic cancer. Advanced Healthcare Materials 14:e2500546

doi: 10.1002/adhm.202500546

[6]

Badr N, Elshof LT, Houvast RD, de Muynck LDAN, Crobach ASLP, et al. 2025. Evaluation of tumor targets selected from public genomic databases for imaging of pancreatic ductal adenocarcinoma. Scientific Reports 15:17102

doi: 10.1038/s41598-025-00517-1

[7]

Ding Z, Wu J, Ye Y, Zhong Y, Yan L, et al. 2025. A novel signature predicts prognosis in pancreatic cancer based on tumor membrane-associated genes. Heliyon 11:e42791

doi: 10.1016/j.heliyon.2025.e42791

[8]

Arseneau RJ, Kempster E, Bekkers C, Samson T, Gala-Lopez BL, et al. 2025. Claudin 18 (43–14A clone) expression in pancreatic ductal adenocarcinoma: assessment of a potential clinical biomarker for zolbetuximab therapy. Translational Oncology 55:102362

doi: 10.1016/j.tranon.2025.102362

[9]

McHugh KE, Pai RK, Grant RC, Gallinger S, Davison J, et al. 2025. Claudin 18.2 expression in 1404 digestive tract adenocarcinomas including 1175 colorectal carcinomas: distinct colorectal carcinoma subtypes are Claudin 18.2 positive. Modern Pathology 38:100712

doi: 10.1016/j.modpat.2025.100712

[10]

Tojjari A, Idrissi YA, Saeed A. 2025. Emerging targets in gastric and pancreatic cancer: focus on claudin 18.2. Cancer Letters 611:217362

doi: 10.1016/j.canlet.2024.217362

[11]

Park S, Shin K, Kim IH, Hong T, Kim Y, et al. 2023. Clinicopathological features and prognosis of resected pancreatic ductal adenocarcinoma patients with claudin-18 overexpression. Journal of Clinical Medicine 12:5394

doi: 10.3390/jcm12165394

[12]

Röcken C, Höhn AK, Neumann J, Schildhaus HU, Singer S, et al. 2025. Concordance of laboratory assays for claudin 18.2 in gastric cancer tissue samples: independent proficiency testing and a descriptive non-interventional study. Virchows Archiv 487:1117−1125

doi: 10.1007/s00428-025-04138-x

[13]

Isidro RA, Abukhiran I, Dunseth CD, Gosse MD, Humble RM, et al. 2023. Strong annexin A10 expression supports a pancreatic primary and combined Annexin A10, claudin 18, and SOX2 expression supports an esophagogastric origin in carcinomas of unknown primary. The American Journal of Surgical Pathology 47:440−452

doi: 10.1097/PAS.0000000000001994

[14]

Lyu SI, Fretter C, Simon AG, Spielmann SM, Damanakis AI, et al. 2024. Extent and clinical significance of the therapy-relevant tight junction protein Claudin 18.2 in pancreatic ductal adenocarcinoma - real-world evidence. Translational Oncology 47:102044

doi: 10.1016/j.tranon.2024.102044

[15]

Franzina C, Bevere M, Bersani S, Mattiolo P, Ceccon C, et al. 2026. High fidelity of Claudin-18.2 expression in primary and matched metastatic (lymph nodes, peritoneum, and liver) pancreatic ductal adenocarcinoma: a foundation for targeted therapy. Human Pathology 168:106014

doi: 10.1016/j.humpath.2025.106014

[16]

Kyuno D, Yanazume K, Saito AC, Ono Y, Ito T, et al. 2026. Concordance of claudin-18.2 expression in biopsy, resection, and recurrent specimens: implications for zolbetuximab therapy in pancreatic ductal adenocarcinoma. Tissue Barriers 14:2535047

doi: 10.1080/21688370.2025.2535047

[17]

Luchini C, Matkowskyj KA, Kuwata T, Longacre TA, Schirmacher P, et al. 2025. Claudin-18.2 immunohistochemical evaluation in pancreatic cancer specimens: review and recommendations for routine testing and scoring. Virchows Archiv 487:487−499

doi: 10.1007/s00428-025-04222-2

[18]

Zhou T, Hou X, Yan J, Li L, Xie Y, et al. 2024. CD64⁺ fibroblast-targeted vilanterol and a STING agonist augment CLDN18.2 BiTEs efficacy against pancreatic cancer by reducing desmoplasia and enriching stem-like CD8⁺ T cells. Gut 73:1984−1998

doi: 10.1136/gutjnl-2024-332371

[19]

Dominguez Wiscovitch A, Sanchez Mendez RJ, Chuy J. 2025. CLDN18.2-targeted therapy in gastrointestinal cancers. Cancers 17:3764

doi: 10.3390/cancers17233764

[20]

De Sanctis F, Dusi S, Caligola S, Anselmi C, Petrova V, et al. 2024. Expression of the membrane tetraspanin claudin 18 on cancer cells promotes T lymphocyte infiltration and antitumor immunity in pancreatic cancer. Immunity 57:1378−1393.e14

doi: 10.1016/j.immuni.2024.04.021

[21]

De Moraes FCA, Matheus GTFU, De Assumpção PP, Burbano RMR. 2026. The prognostic value of CLDN18.2 expression in pancreatic ductal adenocarcinoma: a systematic review and individual patient data meta-analysis. Virchows Archiv 488:1087−1099

doi: 10.1007/s00428-025-04306-z

[22]

Wang C, Wu N, Pei B, Ma X, Yang W. 2023. Claudin and pancreatic cancer. Frontiers in Oncology 13:1136227

doi: 10.3389/fonc.2023.1136227

[23]

Wang X, Zhang CS, Dong XY, Hu Y, Duan BJ, et al. 2022. Claudin 18.2 is a potential therapeutic target for zolbetuximab in pancreatic ductal adenocarcinoma. World Journal of Gastrointestinal Oncology 14:1252−1264

doi: 10.4251/wjgo.v14.i7.1252

[24]

Zhang Z, Liu X, Zhou L, Zhang M, Liang Z. 2022. Investigation of clinical application of claudin 18 isoform 2 in pancreatic ductal adenocarcinoma: a retrospective analysis of 302 chinese patients. Histology and Histopathology 37:1031−1040

doi: 10.14670/HH-18-477

[25]

Li WT, Jeng YM, Yang CY. 2020. Claudin-18 as a marker for identifying the stomach and pancreatobiliary tract as the primary sites of metastatic adenocarcinoma. The American Journal of Surgical Pathology 44:1643−1648

doi: 10.1097/PAS.0000000000001583

[26]

Huang B, Trujillo MA, Fujikura K, Qiu M, Chen F, et al. 2020. Molecular characterization of organoids derived from pancreatic intraductal papillary mucinous neoplasms. The Journal of Pathology 252:252−262

doi: 10.1002/path.5515

[27]

Kayikcioglu E, Yüceer RO. 2023. The role of claudin 18.2 and HER-2 in pancreatic cancer outcomes. Medicine 102:e32882

doi: 10.1097/MD.0000000000032882

[28]

Cha H, Amare ED, Jung YK, Oh YH, Jung WY, et al. 2025. High claudin 18.2 expression predicts favorable outcomes in pancreatic ductal adenocarcinoma after curative resection. Anticancer Research 45:4565−4573

doi: 10.21873/anticanres.17802

[29]

Valentini AM, Arborea G, Grassi I, Savino MT, Labarile N, et al. 2025. Claudin 18.2: an attractive marker in pancreatic ductal adenocarcinoma. Oncology Letters 29:140

doi: 10.3892/ol.2025.14886

[30]

Zhou X, Zou L, Xu J, Zhao H. 2025. The ZIC2-claudin-18.2 axis stimulates pancreatic cancer progression and metastasis via activation of the ERK1/2 signaling pathway. The Tohoku Journal of Experimental Medicine 266:247−256

doi: 10.1620/tjem.2024.J114

[31]

Liu J, Hou X, Li L, Bai W, Zhou T, et al. 2026. KRAS mutation-driven O-GlcNAcylation of CLDN18.2 enhances the progression of pancreatic cancer and reduces the efficacy of CLDN18.2-targeted therapy. Gut 75:1169−1185

doi: 10.1136/gutjnl-2025-336277

[32]

Xu Y, Fu J, Henderson M, Lee F, Jurcak N, et al. 2023. CLDN18.2 BiTE engages effector and regulatory t cells for antitumor immune response in preclinical models of pancreatic cancer. Gastroenterology 165:1219−1232

doi: 10.1053/j.gastro.2023.06.037

[33]

Qi C, Zhang P, Liu C, Zhang J, Zhou J, et al. 2024. Safety and efficacy of CT041 in patients with refractory metastatic pancreatic cancer: a pooled analysis of two early-phase trials. Journal of Clinical Oncology 42:2565−2577

doi: 10.1200/JCO.23.02314

[34]

Qi C, Xie T, Zhou J, Wang X, Gong J, et al. 2023. CT041 CAR T cell therapy for Claudin18.2-positive metastatic pancreatic cancer. Journal of Hematology & Oncology 16:102

doi: 10.1186/s13045-023-01491-9

[35]

Yang J, Peng Y, Ding Y, Liu Y, Wang Y, et al. 2024. The clinicopathological and molecular characteristics of endocervical gastric-type adenocarcinoma and the use of Claudin18.2 as a potential therapeutic target. Modern Pathology 37:100569

doi: 10.1016/j.modpat.2024.100569

[36]

Chen J, Xu Z, Hu C, Zhang S, Zi M, et al. 2023. Targeting CLDN18.2 in cancers of the gastrointestinal tract: New drugs and new indications. Frontiers in Oncology 13:1132319

doi: 10.3389/fonc.2023.1132319

[37]

Du F, Xie Y, Wu S, Ji M, Dong B, et al. 2024. Expression and targeted application of claudins family in hepatobiliary and pancreatic diseases. Journal of Hepatocellular Carcinoma 11:1801−1821

doi: 10.2147/JHC.S483861

[38]

Zhou T, Yan J, Zhang Y, Mao G, Hu T, et al. 2026. Trogocytosis-orchestrated CLDN18.2-"dressed" CD8⁺ T cells drive pancreatic cancer progression via glucose metabolic reprogramming-induced cytotoxicity debilitation and systematic immune senescence cascade. Gut 00:Online ahead of print

doi: 10.1136/gutjnl-2025-33579

[39]

Cortiana V, Abbas RH, Chorya H, Gambill J, Mahendru D, et al. 2024. Personalized medicine in pancreatic cancer: the promise of biomarkers and molecular targeting with Dr. Michael J. Pishvaian. Cancers 16:2329

doi: 10.3390/cancers16132329

[40]

Keam SJ. 2024. Zolbetuximab: first approval. Drugs 84:977−983

doi: 10.1007/s40265-024-02056-x

[41]

Kubota Y, Shitara K. 2024. Zolbetuximab for Claudin18.2-positive gastric or gastroesophageal junction cancer. Therapeutic Advances in Medical Oncology 16:17588359231217967

doi: 10.1177/17588359231217967

[42]

Liu F, Zhang Y, Zhang S, Gong J, Zhang M, et al. 2025. Preliminary result of a phase Ib study: efficacy and safety of FG-M108 plus gemcitabine/nab-paclitaxel as first-line (1L) treatment in patients with Claudin18.2-positive locally advanced unresectable or metastatic (LA/m) pancreatic cancer. Journal of Clinical Oncology 43:729

doi: 10.1200/JCO.2025.43.4_suppl.729

[43]

Li J, Pan H, Liu T, Xu N, Zhang Y, et al. 2023. A multicenter, phase 1 study of AB011, a recombinant humanized anti-CLDN18.2 monoclonal antibody, as monotherapy and combined with capecitabine and oxaliplatin (CAPOX) in patients with advanced solid tumors. Journal of Clinical Oncology 41:391

doi: 10.1200/JCO.2023.41.4_suppl.391

[44]

Liu X, Liu W, Wu C, Yuan Y, Chang A, et al. 2026. Research on precision treatment of pancreatic cancer targeted by antibody-drug conjugates. BioScience Trends 20:45−47

doi: 10.5582/bst.2025.01271

[45]

O'Brien NA, McDermott MSJ, Zhang J, Gong KW, Lu M, et al. 2023. Development of a novel CLDN18.2-directed monoclonal antibody and antibody-drug conjugate for treatment of CLDN18.2-positive cancers. Molecular Cancer Therapeutics 22:1365−1375

doi: 10.1158/1535-7163.MCT-23-0353

[46]

Zhang H, Li Y, Kang H, Lan J, Hou L, et al. 2024. Genetically engineered membrane-based nanoengagers for immunotherapy of pancreatic cancer. Journal of Nanobiotechnology 22:104

doi: 10.1186/s12951-024-02369-9

[47]

Zeng Z, Li L, Tao J, Liu J, Li H, et al. 2024. [¹⁷⁷Lu]Lu-labeled anti-claudin-18.2 antibody demonstrated radioimmunotherapy potential in gastric cancer mouse xenograft models. European Journal of Nuclear Medicine and Molecular Imaging 51:1221−1232

doi: 10.1007/s00259-023-06561-1

[48]

Peng C, Oberstein PE. 2025. Emerging therapeutic approaches to pancreatic adenocarcinoma: advances and future directions. Current Treatment Options in Oncology 26:841−865

doi: 10.1007/s11864-025-01352-2

[49]

Wang Y, Gong J, Zhang M, Sun Y, Yang S, et al. 2025. Safety and efficacy of QLS31905 in patients with advanced solid tumors: updated data from phase 1 study. Journal of Clinical Oncology 43:2527

doi: 10.1200/JCO.2025.43.16_suppl.2527

[50]

Saeed A, Overman MJ, Henry JT, Spira AI, Fei N, et al. 2026. Phase 1/2 study of spevatamig (PT886) in combination with gemcitabine plus nab-paclitaxel (GnP) in frontline (1L) treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC). Journal of Clinical Oncology 44:709

doi: 10.1200/JCO.2026.44.2_suppl.709

[51]

Ma Z, Zhou Z, Duan W, Yao G, Sheng S, et al. 2024. DR30318, a novel tri-specific T cell engager for Claudin 18.2 positive cancers immunotherapy. Cancer Immunology, Immunotherapy 73:82

doi: 10.1007/s00262-024-03673-x

[52]

Liu S, Li F, Deng L, Ma Q, Lu W, et al. 2023. Claudin18.2 bispecific T cell engager armed oncolytic virus enhances antitumor effects against pancreatic cancer. Molecular Therapy - Oncolytics 30:275−285

doi: 10.1016/j.omto.2023.08.011

[53]

Anwar MY, Williams GR, Paluri RK. 2021. CAR T cell therapy in pancreaticobiliary cancers: a focused review of clinical data. Journal of Gastrointestinal Cancer 52:1−10

doi: 10.1007/s12029-020-00457-1

[54]

Yu X, Shi S, Zhang J, Wei M, Shen W, et al. 2025. 2220P Adjuvant therapy with claudin18.2-specific CAR T cells in high-risk pancreatic cancer (CT041-ST-05). Annals of Oncology 36:S1149

doi: 10.1016/j.annonc.2025.08.2837

[55]

Zhang W, Zeng M, Ma X, Chen J, Qiao J, et al. 2025. CLDN18.2-targeting STAR-T cell therapy for pancreatic cancer: a strategy to minimize gastric off-tumor toxicity compared to CLDN18.2 CAR-T. Oncogene 44:2440−2452

doi: 10.1038/s41388-025-03414-z

[56]

Ma X, Zhang W, Zeng M, Asavasupreechar T, Kang S, et al. 2024. Systemic tumor regression with synergy therapy: radiotherapy and CAR-T. Cell Death Discovery 10:479

doi: 10.1038/s41420-024-02245-3

[57]

Sun R, Liu Y, Sun Y, Zhou M, Dong Y, et al. 2024. Dual targeting chimeric antigen receptor cells enhance antitumour activity by overcoming T cell exhaustion in pancreatic cancer. British Journal of Pharmacology 181:4628−4646

doi: 10.1111/bph.16505

[58]

Liu Y, Sun Y, Wang P, Li S, Dong Y, et al. 2023. FAP-targeted CAR-T suppresses MDSCs recruitment to improve the antitumor efficacy of claudin18.2-targeted CAR-T against pancreatic cancer. Journal of Translational Medicine 21:255

doi: 10.1186/s12967-023-04080-z

[59]

Du S, Zhang Y, Hao R, Qiu L, Li C, et al. 2026. Preclinical development and a case report of a nanobody-based CLDN18.2 CAR-T IMC002 with reduced on-target off-tumor toxicity. Molecular Cancer Therapeutics 25:701−716

doi: 10.1158/1535-7163.MCT-25-0171

[60]

Sun R, Sun Y, Wu C, Liu Y, Zhou M, et al. 2023. CXCR4-modified CAR-T cells suppresses MDSCs recruitment via STAT3/NF-κB/SDF-1α axis to enhance efficacy against pancreatic cancer. Molecular Therapy 31:3193−3209

doi: 10.1016/j.ymthe.2023.09.010

[61]

Li J, Wu R, Jin X, Yang Y, Jiang K, et al. 2026. FNDC4 drives metastasis and immune evasion in pancreatic cancer. Cancer Research 86:349−366

doi: 10.1158/0008-5472.CAN-25-1001

[62]

Barrett AM, Britton ZT, Carrasco RA, Breen S, Broggi MAS, et al. 2024. Preclinical evaluation of AZD6422, an armored chimeric antigen receptor T Cell targeting CLDN18.2 in gastric, pancreatic, and esophageal cancers. Clinical Cancer Research 30:5413−5429

doi: 10.1158/1078-0432.CCR-24-1853

[63]

Zhao X, Liu J, Zhang Z, Zhou Y, Jin S, et al. 2026. Efficacy and immunomodulatory effect of Claudin18.2-specific IL-7/XCL1 armored CAR-T cells in digestive tract cancer: preclinical and clinical analysis. Signal Transduction and Targeted Therapy 11:87

doi: 10.1038/s41392-026-02621-8

[64]

Yu X, Ying J, Enxiao L, Zhou A, Sun Y, et al. 2025. Claudin18.2 (CLDN18.2) expression and efficacy in pancreatic ductal adenocarcinoma (PDAC): results from a phase I dose expansion cohort evaluating IBI343. Journal of Clinical Oncology 43:4017

doi: 10.1200/JCO.2025.43.16_suppl.4017

[65]

Katoh M, Katoh M. 2024. Claudin 1, 4, 6 and 18 isoform 2 as targets for the treatment of cancer (Review). International Journal of Molecular Medicine 54:100

doi: 10.3892/ijmm.2024.5424

[66]

Xu G, Liu W, Wang Y, Wei X, Liu F, et al. 2024. CMG901, a Claudin18.2-specific antibody-drug conjugate, for the treatment of solid tumors. Cell Reports Medicine 5:101710

doi: 10.1016/j.xcrm.2024.101710

[67]

Liu J, Yang J, Sun Y, Gong J, Yue J, et al. 2025. CLDN18.2–targeting antibody–drug conjugate IBI343 in advanced gastric or gastroesophageal junction adenocarcinoma: a phase 1 trial. Nature Medicine 31:3028−3036

doi: 10.1038/s41591-025-03783-8

[68]

Williams HL, Dias Costa A, Zhang J, Raghavan S, Winter PS, et al. 2023. Spatially resolved single-cell assessment of pancreatic cancer expression subtypes reveals co-expressor phenotypes and extensive intratumoral heterogeneity. Cancer Research 83:441−455

doi: 10.1158/0008-5472.CAN-22-3050